Terms: = Lymphoma AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Clinical Outcome
17 results:
1. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.
Zhou H; Xu-Monette ZY; Xiao L; Strati P; Hagemeister FB; He Y; Chen H; Li Y; Manyam GC; Li Y; Montes-Moreno S; Piris MA; Young KH
Blood Cancer J; 2020 May; 10(5):49. PubMed ID: 32366834
[TBL] [Abstract] [Full Text] [Related]
2. The Intracellular Intensity of CD3 on Aberrant Intraepithelial Lymphocytes Is a Prognostic Factor of the Progression to Overt lymphoma in Refractory Celiac Disease Type II (Pre-Enteropathy-Associated T Cell lymphoma).
García-Hoz C; Crespo L; Lopez N; De Andrés A; Ríos León R; Santón A; Garriga M; Butz E; León F; Roy Ariño G
Dig Dis; 2020; 38(6):490-499. PubMed ID: 32015237
[TBL] [Abstract] [Full Text] [Related]
3. Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.
Lipowska-Bhalla G; Fagnano E; Illidge TM; Cheadle EJ
Leuk Lymphoma; 2016; 57(6):1269-80. PubMed ID: 27050042
[TBL] [Abstract] [Full Text] [Related]
4. Chronic lymphocytic leukemia: a clinical review including Korean cohorts.
Jeon YW; Cho SG
Korean J Intern Med; 2016 May; 31(3):433-43. PubMed ID: 27044858
[TBL] [Abstract] [Full Text] [Related]
5. C-MYC and BCL2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
Akkaya B; Salim O; Akkaya H; Ozcan M; Yucel OK; Erdem R; Iltar U; Undar L
Indian J Pathol Microbiol; 2016; 59(1):41-6. PubMed ID: 26960633
[TBL] [Abstract] [Full Text] [Related]
6. [Increased risk of severe acute graft-versus-host disease in low body mass index patients undergoing haploidentical allogeneic stem cell transplantation].
Chen Y; Xu L; Liu D; Liu K; Chen H; Zhang X; Wang F; Wang J; Wang Y; Han W; Chen Y; Yan C; Zhao T; Huang X
Zhonghua Nei Ke Za Zhi; 2014 Sep; 53(9):710-4. PubMed ID: 25511404
[TBL] [Abstract] [Full Text] [Related]
7. High expression of cathepsin D in non-Hodgkin's lymphomas negatively impacts on clinical outcome.
Nicotra G; Manfroi F; Follo C; Castino R; Fusco N; Peracchio C; Kerim S; Valente G; Isidoro C
Dis Markers; 2010; 28(3):167-83. PubMed ID: 20534902
[TBL] [Abstract] [Full Text] [Related]
8. Cutaneous presentation of post-renal transplant lymphoproliferative disorder: a series of four cases.
Salama S; Todd S; Cina DP; Margetts P
J Cutan Pathol; 2010 Jun; 37(6):641-53. PubMed ID: 19903218
[TBL] [Abstract] [Full Text] [Related]
9. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.
Friedberg JW; Kelly JL; Neuberg D; Peterson DR; Kutok JL; Salloum R; Brenn T; Fisher DC; Ronan E; Dalton V; Rich L; Marquis D; Sims P; Rothberg PG; Liesveld J; Fisher RI; Coffman R; Mosmann T; Freedman AS
Br J Haematol; 2009 Aug; 146(3):282-91. PubMed ID: 19519691
[TBL] [Abstract] [Full Text] [Related]
10. [Factors affecting the prognosis of diffuse large B-cell lymphoma in Chinese].
Weng Y; Gao ZF; Liu K; Zhang WJ; Ke XY; Li M
Zhonghua Nei Ke Za Zhi; 2005 Sep; 44(9):681-3. PubMed ID: 16202261
[TBL] [Abstract] [Full Text] [Related]
11. Growth pattern and distribution of follicular dendritic cells in mantle cell lymphoma: a clinicopathological study of 96 patients.
Schrader C; Meusers P; Brittinger G; Janssen D; Teymoortash A; Siebmann JU; Parwaresch R; Tiemann M
Virchows Arch; 2006 Feb; 448(2):151-9. PubMed ID: 16133361
[TBL] [Abstract] [Full Text] [Related]
12. AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. "On the offensive--the Trojan Horse is being destroyed"--Part B: Malignant lymphoma.
Cheung TW
Cancer Invest; 2004; 22(5):787-98. PubMed ID: 15581059
[TBL] [Abstract] [Full Text] [Related]
13. Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy.
Reijasse D; Le Pendeven C; Cosnes J; Dehee A; Gendre JP; Nicolas JC; Beaugerie L
Inflamm Bowel Dis; 2004 Mar; 10(2):85-90. PubMed ID: 15168806
[TBL] [Abstract] [Full Text] [Related]
14. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.
Ljung T; Karlén P; Schmidt D; Hellström PM; Lapidus A; Janczewska I; Sjöqvist U; Löfberg R
Gut; 2004 Jun; 53(6):849-53. PubMed ID: 15138212
[TBL] [Abstract] [Full Text] [Related]
15. [Salvage therapy in relapsed or refractory malignant lymphoma].
Kashimura T; Murohashi I
Nihon Rinsho; 2000 Mar; 58(3):699-703. PubMed ID: 10741149
[TBL] [Abstract] [Full Text] [Related]
16. Longitudinal colour doppler study of superficial lymph nodes in non-Hodgkin's lymphoma patients on chemotherapy.
Ho SS; Ahuja AT; Yeo W; Chan TC; Kew J; Metreweli C
Clin Radiol; 2000 Feb; 55(2):110-3. PubMed ID: 10657155
[TBL] [Abstract] [Full Text] [Related]
17. Serum levels of interleukin-2 receptor (CD 25) in patients with Hodgkin's disease, with special reference to age and prognosis.
Enblad G; Sundström C; Gronowitz S; Glimelius B
Ann Oncol; 1995 Jan; 6(1):65-70. PubMed ID: 7710984
[TBL] [Abstract] [Full Text] [Related]
